Adverum Biotechnologies Inc (ADVM)
6.86
-0.39
(-5.38%)
USD |
NASDAQ |
Nov 15, 16:00
7.62
+0.76
(+11.08%)
After-Hours: 20:00
Adverum Biotechnologies Research and Development Expense (TTM): 68.22M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 68.22M |
| June 30, 2024 | 68.52M |
| March 31, 2024 | 72.03M |
| December 31, 2023 | 77.68M |
| September 30, 2023 | 84.60M |
| June 30, 2023 | 87.71M |
| March 31, 2023 | 97.37M |
| December 31, 2022 | 99.28M |
| September 30, 2022 | 99.60M |
| June 30, 2022 | 99.82M |
| March 31, 2022 | 92.16M |
| December 31, 2021 | 89.18M |
| September 30, 2021 | 89.38M |
| June 30, 2021 | 81.97M |
| March 31, 2021 | 78.54M |
| December 31, 2020 | 73.31M |
| September 30, 2020 | 61.96M |
| June 30, 2020 | 55.25M |
| March 31, 2020 | 45.04M |
| December 31, 2019 | 40.42M |
| September 30, 2019 | 40.69M |
| June 30, 2019 | 45.22M |
| Date | Value |
|---|---|
| March 31, 2019 | 47.47M |
| December 31, 2018 | 50.13M |
| September 30, 2018 | 50.50M |
| June 30, 2018 | 46.30M |
| March 31, 2018 | 43.57M |
| December 31, 2017 | 39.84M |
| September 30, 2017 | 35.72M |
| June 30, 2017 | 33.81M |
| March 31, 2017 | 33.28M |
| December 31, 2016 | 31.67M |
| September 30, 2016 | 30.96M |
| June 30, 2016 | 30.12M |
| March 31, 2016 | 27.30M |
| December 31, 2015 | 25.46M |
| September 30, 2015 | 25.50M |
| June 30, 2015 | 23.72M |
| March 31, 2015 | 21.69M |
| December 31, 2014 | 16.98M |
| September 30, 2014 | 10.49M |
| June 30, 2014 | 5.293M |
| March 31, 2014 | 2.86M |
| December 31, 2013 | 2.151M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
40.42M
Minimum
Dec 2019
99.82M
Maximum
Jun 2022
78.10M
Average
80.25M
Median
Research and Development Expense (TTM) Benchmarks
| EyePoint Pharmaceuticals Inc | 107.45M |
| Cassava Sciences Inc | 67.84M |
| Regenxbio Inc | 213.82M |
| Editas Medicine Inc | 220.19M |
| Apellis Pharmaceuticals Inc | 320.50M |